We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




New Solution on the Horizon for Mitral Valve Regurgitation

By HospiMedica International staff writers
Posted on 06 Jul 2016
A new semi-rigid annuloplasty ring provides an advanced, catheter-based solution for treating mitral valve regurgitation.

The Valcare Medical (Herzliya Pituach, Israel) Amend Mitral Valve Repair annuloplasty ring is a 'D' shaped device designed to repair the mitral valve and thereby reduce valvular incompetence. More...
The device is delivered via a sub-xiphoid transapical approach with the aid of a delivery catheter inserted through the chest and into the heart under ¬fluoroscopic and echo guidance. The D-shaped ring is then deployed and positioned to match the annulus of the original valve.

A special mechanism provides control for moving and shaping the ring by modifying its geometry. Using a series of remotely activated mechanisms, the complete ring shape is achieved and a series of anchors in four different zones that are independently deployed attach the ring into the annulus. During the implantation procedure, the septal lateral dimension is reduced to achieve better lea¬flet coaptation, thereby reducing or eliminating the mitral regurgitation.

“Valcare's novel technology is a pioneering breakthrough for the treatment of mitral valve regurgitation, and could be a base for additional modalities for treatment of other valve disorders,” said Uri Geiger, chairman of the board Valcare. “The team is currently focusing on adapting the delivery technique to a transeptal approach allowing for deployment of the system through a puncture in the groin, as well as using the system to treat tricuspid incompetence, another extremely common problem.”

Mitral regurgitation (MR), the most common form of valvular heart disease, is a disorder of the heart in which the mitral valve does not close properly, causing regurgitation of blood from the left ventricle through the mitral valve and back into the left atrium. Patients with MR face a dilemma of whether to undergo corrective surgery early, when they might have no or few symptoms, or wait until their condition worsens, triggering the decision to proceed with surgery.

Related Links:
Valcare Medical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Portable Ventilator
Oxivent Oxi4Plus
New
Ultrasonic Dissector
SONICBEAT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.